Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 21Myeloid 18Breast 4Tumor-Agnostic 2Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Neoplasms 2

Interventions

Paclitaxel 57Gemcitabine 51Carboplatin 51Surveys and Questionnaires 48Docetaxel 37Bevacizumab 37pembrolizumab 33Nivolumab 29Cisplatin 28Fluorouracil 24Capecitabine 23Irinotecan 22Erlotinib Hydrochloride 22Sorafenib 20Leucovorin 19Afatinib 19Radiotherapy 18Pemetrexed 18Oxaliplatin 17Trastuzumab 16Ipilimumab 15regorafenib 14Blood Specimen Collection 14130-nm albumin-bound paclitaxel 14olaparib 13Interviews as Topic 13Cetuximab 13Albumin-Bound Paclitaxel 13atezolizumab 12Sunitinib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × bosutinib × Tumor-Agnostic × Clear all
NCT00195260 2013-02-11

Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors

Pfizer

Phase 1 Completed
151 enrolled 21 charts
Tumor-Agnostic

Neoplasms

NCT01001936 2009-10-27

Study Evaluating SKI-606 in Subject With Solid Tumors

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 1 Completed
28 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡